BioContact Presentation | Fall 2008 www.therapurebio.com

of all new products The future of medicine 2

$51B $87B $25B $89B 2001 Protein therapeutic market 2005 2010 2010 Worldwide mobile technology market

You discovered a protein with blockbuster potential Specific Safe Targeted Efficacious Novel 4

Ultimately, to get your product approved you will invest… You are working hard to develop it 5 11 years 5 clinical trials 2,000 patients 39 patents ~$1 billion

6 What about manufacturing?

Discovery Development Marketing Manufacturing 7

Scaling up is not easy Simple Quick Inexpensive Milligrams commercial bench Complex Long lead times - 4-5 years Expensive - $150+ million Kilograms 8

Therapure Biopharma: Overcoming the manufacturing barrier 9

your trusted partner 10 for protein manufacturing

Therapure Biopharma Focus Provide clients access to our biomanufacturing capabilities Product development Protein purification Cell culture Formulation Fill Lyophilization Finishing Advance our pipeline TBI 301 Post-liver transplant & acute and chronic HCV TBI 302 Hepatocellular carcinoma & metastatic colorectal cancer TBI 303 Proprietary protein modification technology TBI 304 Chemotherapy-induced anemia

Experienced Management Team Thomas Wellner President and CEO Dirk Alkema Vice President, Operations Peter Winkley Vice President Finance and Chief Financial Officer David Bell Vice President, Drug Development and Chief Scientific Officer

About Us Therapure Biopharma Inc. Canadian-based privately held biopharmaceutical company wholly owned by Catalyst Fund Limited Partnership II and management. Catalyst Fund Limited Partnership II A private equity fund with over $1B U.S. in capital that is managed by The Catalyst Capital Group Inc., a Toronto based private equity fund manager.

Ideally located

90 minute flight to 60% of the U.S. population 15

Our Unique and Flexible Biomanufacturing Facility 16

130,000 square feet 5,700 sq.ft. of research laboratories 6,300 sq.ft. of QC labs 30,000 sq.ft. clean room manufacturing 28,000 sq.ft. controlled cGMP warehouse 2,200 sq.ft. GMP clinical pilot suites

Large Volume Protein Purification 18

Large Scale Processing Capabilities 19

Large Volume Storage Capacity 20

Central Service Chase 21

CIP Units For Process Equipment 22

Water For Injection 23

Purified Water System 24

Clean Rooms and Access Points to Meet cGMP Requirements 25

QC Laboratories 26

Sterile Fill Suite 27

Support Beyond Manufacturing 28

Biomanufacturing In-licensing Equity partnerships Late-stage products Approved products in new indications Possible targeted investment Joint development Innovative financing Product co-development Process development Formulation Protein purification Fill & finishing Fee for service Enhanced partnerships 29

Therapure (manufacturing) Therapure (finance) $$ (seed capital) $$ (development fees) protein product interest/options 30 Biotech Equity Partnership 30

partnership Biotech Therapure Biopharma Product IP/ development Manufacturing IP/ development 31 Joint Development 31

Therapure Biopharma Inc. Unique and Flexible Scale of production Range of production Expertise Scientific Manufacturing Regulatory Financing opportunities

33 Let bring your biopharmaceutical to the world! www.therapurebio.com